Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-na ïve, HER2-positive advanced gastric cancer
ConclusionsTrastuzumab with SOX had promising activity with well-tolerated toxicities for patients with HER2-positive AGC.Clinical trial registrationUMIN000017602. (Source: Gastric Cancer)
Source: Gastric Cancer - May 17, 2019 Category: Gastroenterology Source Type: research

Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer
ConclusionsThese results demonstrated that CK2 activation was related to paclitaxel resistance and that CX-4945 in combination with paclitaxel could be used as a potential treatment for paclitaxel resistance in GC. (Source: Gastric Cancer)
Source: Gastric Cancer - May 16, 2019 Category: Gastroenterology Source Type: research

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
ConclusionsNivolumab was efficacious and safe as third- or later-line therapy regardless of prior trastuzumab use in patients with advanced G/GEJ cancer. (Source: Gastric Cancer)
Source: Gastric Cancer - May 13, 2019 Category: Gastroenterology Source Type: research

Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study
ConclusionsUnresectable stage IV GC patients could benefit from radical surgery after chemotherapy and achieve long survivals. The main prognostic factor for these patients was the presence of more than one type of extra-gastric metastatic involvement. (Source: Gastric Cancer)
Source: Gastric Cancer - May 7, 2019 Category: Gastroenterology Source Type: research

The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis
This study compared treatment options and outcomes based on the Peritoneal Cancer Index (PCI).MethodsThis retrospective analysis included patients with gastric cancer treated between August 2008 and December 2017 with synchronous peritoneal metastases only diagnosed by laparoscopy. The three treatments were as follows: (1) cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in combination with pre- and postoperative systemic chemotherapy (n = 58), (2) laparotomy/laparoscopy without CRS, but HIPEC in combination with pre- and postoperative systemic chemotherapy (n = ...
Source: Gastric Cancer - May 7, 2019 Category: Gastroenterology Source Type: research

Risk stratification for lymph node metastasis using Epstein –Barr virus status in submucosal invasive (pT1) gastric cancer without lymphovascular invasion: a multicenter observational study
This study investigated the risk for LNM in pT1b GC without LVI based on Epstein –Barr virus (EBV) status in addition to conventional clinicopathological parameters.MethodsIn total, 847 consecutive patients of pT1b GC without LVI who underwent surgery at three high-volume centers between 2005 and 2014 were retrospectively analyzed. Clinicopathological parameters and EBV status were evaluated, and univariate and multivariate analyses were performed to estimate LNM risk. With regard to the presence of those three parameters, risk stratification for LNM was performed and compared with a previously proposed risk classifi...
Source: Gastric Cancer - May 6, 2019 Category: Gastroenterology Source Type: research

The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer
ConclusionsCombined measurement ofSYT13 andCEA mRNA levels in peritoneal lavage fluid could serve as a promising approach to predict peritoneal recurrence of GC. (Source: Gastric Cancer)
Source: Gastric Cancer - May 4, 2019 Category: Gastroenterology Source Type: research

Long-term outcome of endoscopic submucosal dissection for early gastric cancer in patients with severe comorbidities: a comparative propensity score analysis
This study aimed to assess the long-term outcomes of ESD for patients with severe and non-severe comorbidities.MethodsWe enrolled 1081 patients who underwent ESD for EGC between February 2004 and June 2013. Based on the American Society of Anesthesiologists Physical Status (ASA-PS) classification, we defined patients with severe and non-severe comorbidities as ASA-PS 3 and 1/2, respectively. We retrospectively compared the overall survival, risk factors for mortality, and adverse events between these two groups using propensity score matching and inverse probability of treatment weighting.ResultsA total of 488 patients met...
Source: Gastric Cancer - April 23, 2019 Category: Gastroenterology Source Type: research

CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial
AbstractBackgroundSerum prealbumin (PALB) can predict the prognosis of patients with gastric cancer (GC). However, the prognostic value of combination of C-reactive protein and PALB (CRP/PALB) remains unclear.MethodsA total of 419 gastric cancer patients included in a clinical trial (NCT02327481) were analyzed. The present study is a substudy of the trial. Receiver operating characteristic (ROC) curves were generated, and by calculating the areas under the curve (AUC) and the C-index, the discriminative ability of each inflammatory index was compared, including CRP/PALB, C-reactive protein/albumin, Glasgow prognostic score...
Source: Gastric Cancer - April 23, 2019 Category: Gastroenterology Source Type: research

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
AbstractBackgroundWe recently reported the clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using surgical specimens; patients with homogeneously HER2 positive gastric cancer benefitted more from trastuzumab. However, the majority of patients are diagnosed by endoscopic biopsy, and surgical specimens are not available in these patients. The aim of this study is to verify clinical significance of HER2 heterogeneity on trastuzumab efficacy using biopsy specimens.MethodsEighty-seven patients, who received trastuzumab-based chemotherapy and whose endoscopic biopsy specimens were available for HE...
Source: Gastric Cancer - April 23, 2019 Category: Gastroenterology Source Type: research

Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A , and KDM6B , in gastric cancer susceptibility
ConclusionsAll three H3K27me modifier genes are individually associated with gastric cancer susceptibility with synergistic triad interaction. Not only two enzymes with the same function (KDM6A and KDM6B), but also those with opposite functions (EZH2 versus KDM6A or KDM6B) synergistically affect H3K27me consequences such as gastric cancer susceptibility. (Source: Gastric Cancer)
Source: Gastric Cancer - April 23, 2019 Category: Gastroenterology Source Type: research

Correction to: The search, coagulation, and clipping (SCC) method prevents delayed bleeding after gastric endoscopic submucosal dissection
The article “The search, coagulation, and clipping (SCC) method prevents delayed bleeding after gastric endoscopic submucosal dissection”, written by Motoi Azumi, Manabu Takeuchi, Youhei Koseki, Masaru Kumagai, Yoko Kobayashi, Masafumi Takatsuna, Aiko Yoshioka, Seiichi Yoshikawa, Tsutomu Miura, and Shuji Te rai, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 28 September 2018 without open access. (Source: Gastric Cancer)
Source: Gastric Cancer - April 23, 2019 Category: Gastroenterology Source Type: research

A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer
AbstractBackgroundDefective mismatch repair (dMMR) and microsatellite instability (MSI) correlate with gastric cancer (GC) outcome. We hypothesized that MMR genetic polymorphisms that have low-penetrant effects but may cause heterogeneous MMR capability among individuals also affect GC outcome.MethodsThe polymorphisms rs1800734 inMLH1, rs2303428 and rs3732183 inMSH2, rs735943 inEXO1, and rs11797 inTREX1 were selected and analyzed in independent discovery and validation sets that included 167 and 593 patients, respectively. MSI was determined.ResultsIn both the discovery and validation sets, the rs2303428TC  + &thins...
Source: Gastric Cancer - April 15, 2019 Category: Gastroenterology Source Type: research

The expression of the insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications
ConclusionsVIR and CC-IR expressions are frequent in GC, biologically significant and even correlate with the HER2 status, opening avenues for novel putative therapeutic interventions in GC. (Source: Gastric Cancer)
Source: Gastric Cancer - April 15, 2019 Category: Gastroenterology Source Type: research

Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features
ConclusionCNGs at 20q11.21-13.12 happened frequently in HAS and tended to be related to more adverse biobehaviour. The preoperative serum AFP level was a sensitive prognostic biomarker for DFS and OS. (Source: Gastric Cancer)
Source: Gastric Cancer - April 15, 2019 Category: Gastroenterology Source Type: research

Always randomize as late as possible
(Source: Gastric Cancer)
Source: Gastric Cancer - April 8, 2019 Category: Gastroenterology Source Type: research

Where does signet-ring cell carcinoma come from and where does it go?
(Source: Gastric Cancer)
Source: Gastric Cancer - April 8, 2019 Category: Gastroenterology Source Type: research

Correction to: Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer
The correct name of the corresponding author should be “Takaki Yoshikawa”, and not “Takaki Yoshiaki” as given in the original publication of the article. (Source: Gastric Cancer)
Source: Gastric Cancer - April 8, 2019 Category: Gastroenterology Source Type: research

Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset
ConclusionsPostoperative chemotherapy with S-1 monotherapy for gastric cancer is recommended to begin within 8  weeks after surgery. (Source: Gastric Cancer)
Source: Gastric Cancer - April 6, 2019 Category: Gastroenterology Source Type: research

Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study
This study examines patterns of recurrence in patients receiving perioperative chemotherapy with surgery for gastric cancer in a real-world setting.MethodsAll patients diagnosed with gastric adenocarcinoma between 2010 and 2015 who underwent at least preoperative chemotherapy and a gastrectomy with curative intent (cT1N+/cT2-4a,X; any cN; cM0) in 18 Dutch hospitals were selected from the Netherlands Cancer Registry. Additional data on chemotherapy and recurrence were collected from medical records. Rates, patterns, and timing of recurrence were examined. Multivariable Cox proportional hazard analyses were used to determine...
Source: Gastric Cancer - April 4, 2019 Category: Gastroenterology Source Type: research

A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
ConclusionsThe MTD of poziotinib combined with paclitaxel and trastuzumab was 8  mg/day. This combination yielded promising anti-tumor efficacy with manageable toxicity in previously treated patients with HER2-positive GC. (Source: Gastric Cancer)
Source: Gastric Cancer - April 3, 2019 Category: Gastroenterology Source Type: research

Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy?
ConclusionsNAC may cancel out the negative impact of morbidity on the survival in advanced gastric cancer patients. The prophylactic effects by NAC do not depend on the tumor type or histological response. (Source: Gastric Cancer)
Source: Gastric Cancer - April 3, 2019 Category: Gastroenterology Source Type: research

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
ConclusionsPembrolizumab demonstrated antitumor activity and was well tolerated as monotherapy and in combination with chemotherapy in patients with previously untreated advanced gastric/gastroesophageal junction adenocarcinoma.Clinical TrialClinicalTrials.gov NCT02335411 (Source: Gastric Cancer)
Source: Gastric Cancer - March 25, 2019 Category: Gastroenterology Source Type: research

The therapeutic potential of metformin in gastric cancer
AbstractMetformin is a biguanide molecule used since 1957 to treat type 2 diabetes patients. In addition to its hypoglycemic effects, epidemiological studies have shown that metformin can be associated with a decrease in cancer development risk in diabetic populations. Thus, since 2005 this molecule is largely studied for its antitumoural properties in different types of cancer. The potential antitumoural effect of metformin in gastric cancer has been poorly studied. Here, we detailed the different described mechanisms implicated in the antitumoural effect of metformin in gastric cancer, from the signalling pathways to the...
Source: Gastric Cancer - March 21, 2019 Category: Gastroenterology Source Type: research

Genetic variations associated with telomere length confer risk of gastric cardia adenocarcinoma
ConclusionsOur results highlight the importance of both LTL and LTL-related genetic variants to GCA predisposition. (Source: Gastric Cancer)
Source: Gastric Cancer - March 21, 2019 Category: Gastroenterology Source Type: research

Frequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric cancer patients in Brazil
ConclusionsNo unequivocal pathogenic germlineCDH1 variants were identified in Brazilian EOGC patients. Dietary habits may be associated with the EOGC development. (Source: Gastric Cancer)
Source: Gastric Cancer - March 20, 2019 Category: Gastroenterology Source Type: research

Should pylorus-preserving gastrectomy be performed for overweight/obese patients with gastric cancer?
ConclusionsFor overweight/obese patients, LDG and LPPG resulted in similar degrees of postoperative weight loss, with patients achieving near-ideal body weight. The postoperative nutritional advantages of LPPG were confirmed. LPPG seemed to be better even for overweight/obese patients who meet indication criteria. (Source: Gastric Cancer)
Source: Gastric Cancer - March 19, 2019 Category: Gastroenterology Source Type: research

Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy
ConclusionsIn patients with recurrent disease who underwent D2 gastrectomy followed by adjuvant S-1 monotherapy, 80% of recurrences occur within 3  years after gastrectomy. The timing of recurrence is not significantly different among substages. Although the rates of local recurrence and lymph node and liver metastasis plateau after 3 years, peritoneal and the other hematogenous metastases increase within 5 years. (Source: Gastric Cancer)
Source: Gastric Cancer - March 15, 2019 Category: Gastroenterology Source Type: research

DNA methylation genome-wide analysis in remnant and primary gastric cancers
ConclusionsThis study demonstrated that promoter methylation status in PGC is higher than in RGC. This result may reflect the effects of the absence ofHelicobacter pylori on the reduced DNA methylation in the remnant stomach. (Source: Gastric Cancer)
Source: Gastric Cancer - March 12, 2019 Category: Gastroenterology Source Type: research

The role of FBXW7 , a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors
ConclusionFBXW7 is a potential predictive marker of recurrence after curative resection of GISTs. FBXW7 expression may help identify patients benefitting from adjuvant therapy more precisely compared with a conventional risk stratification model. (Source: Gastric Cancer)
Source: Gastric Cancer - March 11, 2019 Category: Gastroenterology Source Type: research

Duodenal stump reinforcement might reduce both incidence and severity of duodenal stump leakage after laparoscopic gastrectomy with Roux-en-Y reconstruction for gastric cancer
AbstractBackgroundAlthough duodenal stump leakage (DSL) is a relatively rare complication after gastrectomy with Roux-en-Y (R-Y) reconstruction, it is difficult to treat and can be fatal. We investigated the impact of duodenal stump reinforcement on DSL after laparoscopic gastrectomy with R-Y reconstruction for gastric cancer.MethodsThis retrospective study of 965 patients with gastric cancer who underwent laparoscopic distal or total gastrectomy (LDG or LTG) with R-Y reconstruction compared surgical outcomes between two groups, the duodenal stump reinforcement group (reinforcement group) (n = 895) and that w...
Source: Gastric Cancer - March 9, 2019 Category: Gastroenterology Source Type: research

Nishi Memorial Award in Gastric Cancer
(Source: Gastric Cancer)
Source: Gastric Cancer - March 9, 2019 Category: Gastroenterology Source Type: research

Surgical outcomes and risk assessment for anastomotic complications after laparoscopic proximal gastrectomy with double-flap technique for upper-third gastric cancer
This study was a retrospective review aimed to demonstrate details of surgical outcomes and to assess risk factors for anastomotic complications using pre-operative CT image after LPG with DFT (LPG –DFT).MethodsPatient background data, surgical outcomes, post-operative courses, and complications for patients who underwent LPG –DFT from January 2013 to June 2017 were collected. In addition to the details of short-term outcomes, risk factors for anastomotic stricture and gastroesophageal reflux were analyzed.ResultsThe study sample was 147 patients, including 139 patients with upper-third gastric cancer and 8 pat...
Source: Gastric Cancer - March 6, 2019 Category: Gastroenterology Source Type: research

Operation time as a simple indicator to predict the overcoming of the learning curve in gastric cancer surgery: a multicenter cohort study
ConclusionOvercoming the learning curve of distal gastrectomy for gastric cancer can be better predicted by operation time rather than by a combination of postoperative clinical parameters. It is recommended that surgeons initially operate on early stage cancer patients before overcoming the learning curve. (Source: Gastric Cancer)
Source: Gastric Cancer - March 4, 2019 Category: Gastroenterology Source Type: research

Oncological feasibility of laparoscopic subtotal gastrectomy compared with laparoscopic proximal or total gastrectomy for cT1N0M0 gastric cancer in the upper gastric body
ConclusionsLsTG could be an oncologically acceptable procedure for cT1N0M0 gastric cancer in the upper gastric body. LsTG could be one option for such disease. (Source: Gastric Cancer)
Source: Gastric Cancer - March 4, 2019 Category: Gastroenterology Source Type: research

Gastric cancer mortality rates among US and foreign-born persons: United States 2005 –2014
ConclusionsEfforts directed at reducing the prevalence of gastric cancer risk factors could help reduce the elevated burden observed among foreign-born individuals and US-born minority groups. (Source: Gastric Cancer)
Source: Gastric Cancer - March 4, 2019 Category: Gastroenterology Source Type: research

Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501)
ConclusionsNAC for type 4 and large type 3 gastric cancer followed by D2 gastrectomy can be safely performed without increasing the morbidity or mortality. (Source: Gastric Cancer)
Source: Gastric Cancer - March 2, 2019 Category: Gastroenterology Source Type: research

Correction to: Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis
In the original publication of this article, most of the reference citations in Tables 1 and 2 were published incorrectly. The corrected tables are given in this correction. (Source: Gastric Cancer)
Source: Gastric Cancer - March 1, 2019 Category: Gastroenterology Source Type: research

GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer
ConclusionTaken together, GC1118 alone or in combination with cytotoxic chemotherapeutic agents exerted more potent anti-tumor effects than cetuximab in GC cells, regardless ofKRAS status. These findings support the further clinical development of GC1118 for the treatment of GC. (Source: Gastric Cancer)
Source: Gastric Cancer - February 27, 2019 Category: Gastroenterology Source Type: research

Enhanced recovery versus conventional care in gastric cancer surgery: a meta-analysis of randomized and non-randomized controlled trials
AbstractIntroductionEnhanced recovery after surgery (ERAS) protocols have been successfully integrated into peri-operative management of different cancer surgeries such as colorectal cancer. Their value for gastric cancer surgery, however, remains uncertain.MethodsA search for randomized and observational studies comparing ERAS versus conventional care in gastric cancer surgery was performed according to PRISMA guidelines. Random-effects meta-analyses with inverse variance weighting were conducted, and quality of included studies was assessed using the Cochrane risk-of-bias tool and Newcastle-Ottawa scale (PROSPERO: CRD420...
Source: Gastric Cancer - February 25, 2019 Category: Gastroenterology Source Type: research

Author ’s reply to letter to the editor: “After propensity score matching in long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy”
(Source: Gastric Cancer)
Source: Gastric Cancer - February 21, 2019 Category: Gastroenterology Source Type: research

Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401
ConclusionsThis trial confirmed the safety of LATG/LAPG. After the non-inferiority of LADG is confirmed in our phase III trial (JCOG0912), LATG/LAPG is expected to be established as one of the standard treatments for clinical stage I gastric cancer. (Source: Gastric Cancer)
Source: Gastric Cancer - February 20, 2019 Category: Gastroenterology Source Type: research

Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients
ConclusionHypoalbuminemia appears to be a risk factor for AGC-associated VTE. DOACs are effective to AGC-associated VTE, but careful observation of bleeding events is required. (Source: Gastric Cancer)
Source: Gastric Cancer - February 20, 2019 Category: Gastroenterology Source Type: research

Pylorus-preserving gastrectomy for early cancer involving the upper third: can we go higher?
AbstractBackgroundPylorus-preserving gastrectomy (PPG) is commonly performed for early gastric cancer (EGC) located in middle third of the stomach. We investigated the surgical, oncological, and functional outcomes of PPG involving the upper third of stomach.MethodsWe included all patients of the period 2013 –2016 who underwent PPG, distal subtotal gastrectomy (DSG), and total gastrectomy (TG) for EGC involving the upper third by carefully defining the localization. Surgical, oncological, and functional outcome analyses included postoperative morbidity, lymph-node metastasis, tumor recurrence, postope rative body wei...
Source: Gastric Cancer - February 19, 2019 Category: Gastroenterology Source Type: research

Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M
ConclusionsOSM –OSMR contributes to GC progression through activating STAT3/FAK/Src signaling, and OSMR is transcriptionally activated by SP1. (Source: Gastric Cancer)
Source: Gastric Cancer - February 18, 2019 Category: Gastroenterology Source Type: research

Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer
ConclusionsConsidering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. (Source: Gastric Cancer)
Source: Gastric Cancer - February 18, 2019 Category: Gastroenterology Source Type: research

Digital image analysis-based scoring system for endoscopic ultrasonography is useful in predicting gastrointestinal stromal tumors
ConclusionsThe scoring system based on the information of digital image analysis is useful in predicting GISTs in case of GMTs that are 2 –5 cm in size. (Source: Gastric Cancer)
Source: Gastric Cancer - February 18, 2019 Category: Gastroenterology Source Type: research

Epigenetic downregulation of MUC17 by H. pylori infection facilitates NF- κB-mediated expression of CEACAM1-3S in human gastric cancer
ConclusionsMUC17 was epigenetically downregulated in GC withH. pylori infection. MUC17 inhibitedH. pylori CagA translocation via attenuation of NF- κB-mediated expression of CEACAM1-3S in GC cells. Thus, MUC17 may serve as a valuable prognostic biomarker forH. pylori-associated GC. (Source: Gastric Cancer)
Source: Gastric Cancer - February 18, 2019 Category: Gastroenterology Source Type: research

Mediterranean diet adherence and risk of esophageal and gastric cancer subtypes in the Netherlands Cohort Study
ConclusionsHigher MD adherence was associated with reduced risks of ESCC, GCA, and GNCA in the NLCS. However, the decreased ESCC risk might be limited to men. (Source: Gastric Cancer)
Source: Gastric Cancer - February 15, 2019 Category: Gastroenterology Source Type: research

Internal hernia after gastrectomy for gastric cancer in minimally invasive surgery era
This study aimed to analyze the clinical features and risk factors for internal hernia after gastrectomy for gastric cancer.MethodsWe retrospectively analyzed internal hernia after gastrectomy for gastric cancer in 6474 patients between January 2003 and December 2016 at Seoul National University Bundang Hospital. Multivariable logistic regression was performed to evaluate risk factors.ResultsInternal hernias identified by computed tomography or surgical exploration were 111/6474 (1.7%) and the median interval time was 450 days after gastrectomy. Fourteen (0.9%) of the 1510 patients who underwent open gastrectomy and 97 (2....
Source: Gastric Cancer - February 13, 2019 Category: Gastroenterology Source Type: research